



BioInvent

Translating
cancer antibody
biology

into
innovative
immuno-oncology
therapies

BioInvent is a clinical stage company focused on the development of novel, first-in-class immuno-modulatory antibodies for the treatment of cancer. Our powerful discovery engine is based on our unique development tool F.I.R.S.T™, where patient material is the foundation and simultaneously identifies the clinically most relevant targets in a disease model and matching antibodies.

The proprietary antibody library n-CoDeR® contains antibodies that bind specifically and strongly to their targets. Platform fuels pipeline and enables revenue generating deal flow. Milestone-generating partnerships with Pfizer, CASI pharmaceuticals, XOMA and Mitsubishi Tanabe as well as a clinical trial collaboration and supply agreement with Merck.

FAST FACTS

Ticker

Nasdaq Stockholm:-
BINV

Share Price¹

SEK 59.00

52-week range¹

SEK 31.93-63.00

Market Cap¹

~USD 425 million

Cash & equivalents²

~USD 117 million

Shares outstanding²

58.47 million

Avg Daily Volume

100,732


Headquarters:

Lund, Sweden

¹ As of June 4, 2021

² As of March 31, 2021

TECHNOLOGY PLATFORM



F.I.R.S.T. Differentiators

1. Patient-Centric: development of the therapeutically most active antibodies using primary patient cells throughout discovery
2. Matching: Simultaneously identifies clinically relevant disease-associated targets and antibodies that bind to them
3. Novel: Allows for discovery of novel targets and mAbs

PIPELINE WITH FOUR CLINICAL PROGRAMS

Program	Indication	Discovery	Preclinical	Phase 1	Phase 2	Partner
Target: FcγRIIB						
BI-1206/rituximab	NHL (MCL, MZL, iFL)	[Progress bar: Discovery, Preclinical, Phase 1, Phase 2]				CASI
BI-1206/pembrolizumab	Solid tumors	[Progress bar: Discovery, Preclinical, Phase 1, Phase 2]				MSD, CASI
BI-1607	Solid tumors	[Progress bar: Discovery, Preclinical, Phase 1, Phase 2]				
Target: CTLA-4 and TNFR2						
BT-001 (CTLA-4, GM-CSF)	Solid tumors	[Progress bar: Discovery, Preclinical, Phase 1, Phase 2]				transgene
BI-1808 (TNFR2)	Solid tumors	[Progress bar: Discovery, Preclinical, Phase 1, Phase 2]				
BI-1910 (TNFR2)	Solid tumors	[Progress bar: Discovery, Preclinical, Phase 1, Phase 2]				

BI-1206 in two clinical studies

Selectively binds to FcγRIIB, the brakes of the innate immune system, overexpressed in several forms of NHL and solid tumors. By blocking FcγRIIB, BI-1206 is expected to recover and enhance the activity of IO therapy.

BI-1206 is developed to re-establish the clinical effect of existing cancer treatments such as pembrolizumab and rituximab, drugs with combined global sales of approximately USD 21 billion annually.

BT-001

A best-in-class oncolytic virus encoding BioInvent's Treg-depleting anti-CTLA-4 antibody & GM-CSF cytokine.

Designed for strong and sustained anti-tumor activity and for better safety vs current anti-CTLA-4 treatment

BI-1808

A first-in-class anti-TNFR2 antibody generated from its proprietary n-CoDeR® library and unique F.I.R.S.T™ discovery tool. TNFR2 is particularly upregulated in the tumor micro-environment and is important for tumor expansion and survival.